TEX46 and systemic lupus erythematosus: As opposed to reduced TEX being beneficial in cancer, reduced TEX has been associated with disease progression and increased severity in some autoimmune diseases including systemic lupus erythematosus (SLE), antineutrophil cytoplasmic antibody-associated vasculitis, and type 1 diabetes (T1D) (8–11).